CD8A and neoplasm: Breast cancer cells with epithelial markers express high levels of MHC-I, low levels of PD-L1, and contain CD8+ T cells and M1 macrophages within the tumor stroma, which might contribute to a better response to anti-CTLA-4 treatment.